Since CTLA-4 is a key mediator of Treg suppression [42], it is possible that inhibition of Treg function by anti-CTLA-4 antibodies might prevent expanded Treg from limiting anti-tumour immunity in these individuals, perhaps explaining why therapies targeting both PD-1 and CTLA-4 work well together. This evidence concerns the gene CTLA4 and neoplasm.